Verification Pending — official Grants.gov candidate (posted)
PAR-25-069
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Official Grants.gov opportunity PAR-25-069 from National Institutes of Health. Requires full eligibility, amount, controlling deadline, award-type and duplication QA before publication.
FundingApplicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Deadline2027-01-07 (official deadline clock time and time zone must be checked in NOFO)
Last verifiedAtlas review
Required next actionReview the official full announcement, amendments and submission portal requirements before applying.
Broad Eligibility
County governments; Private institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal governments (Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; City or township governments; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; For profit organizations other than small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); Small businesses; State governments; Special district governments; Independent school districts
Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: PAR-25-069
Official listed status: posted
Closing information: 2027-01-07 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Applicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Applicant categories in federal synopsis: County governments; Private institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal governments (Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; City or township governments; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; For profit organizations other than small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); Small businesses; State governments; Special district governments; Independent school districts
Federal synopsis
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.
Official Grants.gov opportunity and NOFO
From Funding to Implementation · School Health Solution
Turn school-health funding into a clinically capable care model.
Dr. Miltie N9+ can support clinician-directed remote exams in school settings, helping care teams move beyond video-only encounters when a funded program calls for stronger pediatric access.
Source verificationOfficial government source · www.grants.govAtlas last verified this record during its latest review. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
